In a patient with prostate cancer and a chronic Foley catheter who has completed a 7‑day course of ceftriaxone, is afebrile with a normal white‑cell count, but continues to have gross hematuria, what is the appropriate management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Persistent Gross Hematuria After Completing Antibiotics Requires Urologic Evaluation

In this patient with prostate cancer, chronic Foley catheter, and persistent gross hematuria despite completing ceftriaxone treatment and resolution of infection, you must refer for urgent urologic evaluation with cystoscopy and imaging. 1

Immediate Management Approach

The continued gross hematuria is not an indication to continue or change antibiotics. The patient is afebrile with normal white cell count, indicating the infection has resolved. The hematuria requires a different diagnostic approach.

Why Urologic Referral is Mandatory

  • All adults with gross hematuria require urologic evaluation, even if self-limited 1
  • The probability of underlying cancer or clinically significant pathology with gross hematuria consistently exceeds 10% and can be >25% in referral series 1
  • This patient has multiple high-risk features:
    • Known prostate cancer
    • Age (implied elderly with prostate cancer)
    • Chronic catheterization

What NOT to Do

Do not:

  • Continue or escalate antibiotics without evidence of active infection 2
  • Obtain urinary cytology or urine-based molecular markers as initial evaluation 1
  • Delay referral waiting for hematuria to resolve spontaneously
  • Assume the bleeding is solely catheter-related trauma

Potential Etiologies to Investigate

The urologic evaluation should assess for:

  1. Bladder pathology - tumor, stones, radiation cystitis (if prior radiation)
  2. Catheter-related complications - chronic inflammation, bladder stones 3
  3. Upper tract sources - requires imaging
  4. Prostate cancer progression - local invasion or bleeding

Catheter Management Considerations

While awaiting urology consultation:

  • Ensure adequate hydration to prevent clot retention
  • Consider gentle bladder irrigation if clots are obstructing flow
  • The catheter itself may need replacement or removal depending on urologic assessment
  • Chronic catheterization increases risk of bladder stones and local complications 4

Common Pitfall

Anchoring bias: Do not attribute persistent hematuria solely to the recent UTI or catheter trauma. The combination of prostate cancer, chronic catheterization, and gross hematuria mandates structural evaluation regardless of infection status 1, 3.

The ceftriaxone has done its job treating the infection. The persistent bleeding requires cystoscopy and imaging to rule out malignancy, stones, or other structural pathology that impacts both morbidity and mortality.

References

4
Research

Catheter-associated urinary tract infections.

Infectious disease clinics of North America, 1997

Related Questions

How should I manage a 60-year-old man with a suprapubic catheter who has a nitrate-positive urine dipstick?
In a 67-year-old man presenting with burning epigastric pain, urinary‑tract‑infection‑like symptoms, and hypercalcemia, what are the differential diagnoses?
What is the appropriate management for a 70‑year‑old male with benign prostatic hyperplasia who presents with cloudy, foul‑smelling urine, urinary frequency, urgency, and fever?
In a 75-year-old man with an indwelling urinary catheter for benign prostatic hyperplasia who is asymptomatic but has a urine culture growing Klebsiella (>10⁵ CFU/mL) susceptible to ciprofloxacin, amikacin, and co‑trimoxazole, should antimicrobial therapy be started or is the appropriate management simply to proceed with the scheduled catheter change?
In a 12-year-old child with cerebral palsy on levetiracetam (Keppra), being treated with intravenous ceftriaxone for a Proteus mirabilis febrile urinary tract infection, who is clinically improving but shows a rising C‑reactive protein after 5 days while the complete blood count remains normal, how should management be adjusted?
Can a patient with systemic lupus erythematosus use diclofenac for tooth pain?
In a patient with small‑cell lung cancer who has completed chemotherapy and has residual thoracic disease, what is the recommended management if new pulmonary nodules are also identified?
In a patient with chronic Foley catheter and prostate cancer who received seven days of ceftriaxone 1 g IV daily for Proteus mirabilis urinary infection, is it appropriate to complete the seven‑day course without extending antibiotics, given afebrile status, normal white blood cell count, persistent gross hematuria and anemia?
What is the appropriate second‑line systemic therapy for a patient with small‑cell lung cancer who has completed cisplatin‑etoposide and now has residual thoracic disease with new pulmonary nodules?
What is the recommended duration of contraception for women and men after possible Zika virus exposure to prevent congenital infection?
When can a patient safely return to work after a myocardial infarction with stent placement, considering the physical demands of their job?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.